BLUEPRINT MEDICINES CORP's ticker is BPMC and the CUSIP is 09627Y109. A total of 233 filers reported holding BLUEPRINT MEDICINES CORP in Q4 2019. The put-call ratio across all filers is 1.49 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $19,469,000 | +95.9% | 249,598 | +46.9% | 17.31% | +9.4% |
| Q1 2020 | $9,936,000 | -75.8% | 169,900 | -69.6% | 15.82% | +0.8% |
| Q3 2019 | $41,098,000 | -6.8% | 559,381 | +19.6% | 15.69% | +8.5% |
| Q2 2019 | $44,116,000 | +17.8% | 467,682 | 0.0% | 14.47% | +48.5% |
| Q1 2019 | $37,438,000 | +48.5% | 467,682 | 0.0% | 9.74% | +17.7% |
| Q4 2018 | $25,213,000 | +61.5% | 467,682 | +133.8% | 8.28% | +140.4% |
| Q3 2018 | $15,612,000 | -1.6% | 200,000 | -20.0% | 3.44% | +0.8% |
| Q2 2018 | $15,870,000 | -56.7% | 250,000 | -37.5% | 3.42% | -57.2% |
| Q1 2018 | $36,680,000 | +21.6% | 400,000 | 0.0% | 7.99% | -5.6% |
| Q4 2017 | $30,164,000 | -7.4% | 400,000 | -14.5% | 8.46% | -5.7% |
| Q3 2017 | $32,583,000 | +39.8% | 467,682 | +1.7% | 8.98% | +17.9% |
| Q2 2017 | $23,308,000 | +123.8% | 460,000 | +76.7% | 7.61% | +90.5% |
| Q1 2017 | $10,413,000 | +23.7% | 260,400 | -13.2% | 4.00% | +9.3% |
| Q4 2016 | $8,415,000 | – | 300,000 | – | 3.66% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Boxer Capital, LLC | 705,159 | $12,728,000 | 12.46% |
| BVF INC/IL | 2,640,251 | $47,657,000 | 11.79% |
| Casdin Capital, LLC | 321,300 | $5,799,000 | 6.66% |
| Opaleye Management Inc. | 220,000 | $3,971,000 | 2.48% |
| PFM Health Sciences, LP | 1,420,511 | $25,640,000 | 0.79% |
| Perceptive Advisors | 404,404 | $7,299,000 | 0.64% |
| Partner Investment Management, L.P. | 18,788 | $339,000 | 0.55% |
| Visium Asset Management, LP | 1,265,025 | $22,834,000 | 0.39% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 661,717 | $11,944,000 | 0.39% |
| Virtus ETF Advisers LLC | 10,484 | $189,000 | 0.26% |